The long-term, cash squeeze, high dividend growth strategy is commonly used by companies all over the world. Many investors are misled by the offset that occurs in company data when this strategy is deployed.

Yesterday we presented part 1 of our analysis on the biosimilar pharmaceuticals market. Today we'll be presenting part 2 and picking up where we left off with a Brief History of Biosimilars. Brief History

Introduction The type of pharmaceutical drug being referenced throughout this discussion goes by many different names. These terms include “biopharmaceuticals”, “biological medical products”, or simply

Our Model Portfolio contains companies that have attained a status referred to as an SDG. But what is that? How does a company attain such a status? An SDG is a company that pays a dividend which increases,

In Part 1 we looked at some of the history of the recent elevated interest in dividend growth investing and dividend stocks in general. In this article, the discussion continues with other parameters that

The meaning of the term “dividend growth investing” (DGI) has become extremely varied. Given its wide usage, one can’t assume any particular strategy is referenced whenever the term is used. Most practitioners

The term “dividend growth investing” (DGI) has taken on many different meanings. This term is used by several hundred funds and ETFs, all of which vary in their approach. Among the practitioners of this

Dividend Growth Investing (DGI) is an amazing strategy that can return steady income over long-time frames. Crypto investing is very interesting because of the aspects of emerging technology and exponential